Introduction {#S0001}
============

Esophageal cancer (EC) is the eighth most common malignancy and the sixth most common cause of cancer-related deaths worldwide.[@CIT0001] More than 50% of patients are diagnosed at a late stage and therefore lose the opportunity for surgical intervention.[@CIT0002] Chemoradiotherapy is the main treatment method for these patients and includes neoadjuvant chemoradiotherapy and definitive chemoradiotherapy.[@CIT0003],[@CIT0004] For these patients, early prediction of tumor response is very helpful for optimizing the treatment strategy in a timely manner, thus improving the local control rate and the survival rate. It has been reported that tumor response is affected by the tumor itself and the host immune status.[@CIT0005],[@CIT0006]

Abnormal glucose metabolism is one of the core characteristics of tumor cell function and is considered to be an important index for tumor diagnosis and the evaluation of tumor biological behavior.[@CIT0007],[@CIT0008] 18F-fluorodeoxy-glucose Positron emission tomography/computed tomography (^18^F-FDG PET/CT), as a commonly used clinical molecular imaging technique, can determine the metabolism of tumor cells at the molecular level by measuring the uptake of FDG in tumor tissues, and it has been widely used in predicting of the disease status of solid tumors.[@CIT0009]--[@CIT0013] It has been reported that patients with a high baseline SUVmax have poor primary tumor responses in lymphoma, cervical cancer, and lung cancer.[@CIT0010]--[@CIT0014] However, for EC patients undergoing CCRT, the correlation between baseline SUVmax and primary tumor response has not been consistent.[@CIT0015]--[@CIT0020] Although some clinical studies suggest that primary tumors with lower SUVmax values can achieve higher objective remission rates,[@CIT0015]--[@CIT0017] some data indicate that baseline SUVmax values have no predictive value with regards to the primary tumor response.[@CIT0018],[@CIT0019] Moreover, few studies have reported that patients with higher SUVmax values have better pathologic remissions after neoadjuvant CCRT.[@CIT0020] The inconsistency of these studies suggests that using SUVmax alone is not sufficient to predict tumor response in patients who receive CCRT.

On the other hand, as part of the host's anti-tumor response, the immune system plays an important role in the development, progression and metastasis of cancer.[@CIT0021],[@CIT0022] Lymphocyte-monocyte ratio (LMR), as the ratio between absolute peripheral lymphocyte and monocyte counts, can reflect the immune status of the host and affect tumor progression. It has been reported that peripheral LMR is associated with tumor response and prognosis in lymphoma, nasopharyngeal carcinoma, lung cancer, colorectal cancer and other solid tumors.[@CIT0023]--[@CIT0028] For esophageal cancer, a predictive role of the baseline peripheral LMR has also been reported.[@CIT0029],[@CIT0030] These studies have mainly focused on operable patients and explored the predictive value of peripheral LMR in terms of long-term effects, but few studies have focused on predicting tumor response in inoperable treated patients, which is also important for determining clinical treatment options.

Hence, in this study, we explored the predictive value of baseline SUVmax combined with peripheral LMR in patients with esophageal cancer undergoing CCRT based on two aspects: abnormal glucose metabolism by tumor cells and the anti-tumor immune response of the host.

Materials And Methods {#S0002}
=====================

Patient Selection And Characteristics {#S0002-S2001}
-------------------------------------

The presence of disease was histopathologically confirmed in all patients, the pathological type was esophageal squamous cell carcinoma, and all patients had a Karnofsky Performance Scale (KPS) score ≥70. In addition, all patients had a PET/CT examination one week before any systematic treatment as well as a routine blood test. All patients met the following criteria: (1) no history of other malignancy; (2) no distant metastasis (M0) or second primary tumor; (3) no acute infections or hematologic and autoimmune diseases as well as other diseases that may cause inflammation; (4) available clinical information; (5) locally advanced disease based on the 7th edition of the American Joint Committee on Cancer guidelines (AJCC7th edition). Using a hospital information system, we extracted the following baseline characteristics: age, gender, drinking history, smoking history, tumor location, TNM stage, and tumor stage. All of the patients were Chinese. The ethics committee of Shandong Cancer Hospital and Institute approved the study. All participants signed informed consents, and this study was conducted in accordance with the Declaration of Helsinki.

Treatment Protocols And Response Assessment {#S0002-S2002}
-------------------------------------------

All patients received CCRT as their treatment option. All radiation treatments were performed using either 3D-CRT or intensity-modulated radiation therapy (IMRT). Patients were treated with a total dose of 50--64 Gy administered once daily in 25--32 fractions with a standard fractionation (ie 1.8 or 2.0 Gy/fractions, 5 days/week). Chemotherapy began on Day 1 concurrent with the initial radiation treatments, cycled every 28 days for 2--4 cycles for 2 cycles with radiation followed by 2 cycles without radiation. 5-Fluorouracil (700 mg/m2) was administered intravenously (iv) continuous infusion over 24 hrs daily on Days 1--4, and cisplatin (75 mg/m2) was administered by iv on Day 1. Due to the lack of endoscopic ultrasound examination in some patients and to the heterogeneity of the criteria, we did not consider the endoscopic results when evaluating tumor response. Due to economic factors and other reasons, a second PET-scan to assess the response is not available. Evaluation of the primary tumor response to treatment was performed by using esophagography and computed tomography scan 2--4 weeks after completion of CCRT. Tumor response was defined as a complete response (CR) or a partial response (PR); nonresponse was defined as stable disease (SD) or progressive disease (PD) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A primary tumor response that fulfilled the CR criteria and PR criteria was defined as an objective response (OR) (OR=CR+PR), and other responses were defined as non-ORs.

Laboratory Data {#S0002-S2003}
---------------

As part of the laboratory examinations, peripheral blood was counted using Sysmex XT-2000i Automated Hematology Analyzer (GMI, MN, USA) before the initiation of systemic treatment, and both peripheral lymphocytes and monocytes were counted using an automated hematology analyzer. In this study, the peripheral LMR was calculated as the ratio between absolute counts of peripheral lymphocytes and monocytes.

PET/CT Scanning And Image Analysis {#S0002-S2004}
----------------------------------

All patients underwent PET/CT examination one week before treatment using an advanced PET/CT scanner. The patients were asked to fast and rest at least 6 h before the examination. Then, 5.50 MBq/kg of 18F-FDG was injected into the patients after ensuring that blood glucose levels met the requirement. Sixty minutes later, whole-body PET and CT scans were performed from the top of the skull to the proximal thigh for 5 min per field of view, each covering 14.5 centimeters, with an axial sampling at 4.25 millimeters per slice. PET data sets were reconstructed with CT-derived attenuation correction using the ordered subset expectation maximiza¬tion algorithm. The PET parameters were measured using an elliptical region of interest (ROI) over the suspicious area showing increased FDG uptake compared to that of the surrounding esophageal tissue. The high¬est pixel value of the SUV was recorded as the SUVmax.

Statistical Analysis {#S0002-S2005}
--------------------

The continuous variables baseline SUVmax and peripheral LMR were dichotomized using optimal cut-off values determined by receiver operating characteristics (ROC) curves. Fisher's exact or chi-squared tests were used to compare the differences in baseline data regarding clinicopathological parameters (i.e., age, gender, drinking history, smoking history, tumor location, clinical tumor stage, clinical node stage, tumor stage and tumor response) between different SUVmax and LMR groups. Univariate and multivariate logistic regression analyses were used to analyze independent predictors of clinical tumor response. Fisher's exact tests were used to compare the different tumor responses between each group based on SUVmax and LMR status, and the P-value was calibrated by the Bonferroni correction method. The analyses were performed with SPSS 22.0 program (SPSS Inc, Chicago, IL, USA), and a two-sided P-value less than 0.05 was considered statistical significance.

Results {#S0003}
=======

Patient Characteristics {#S0003-S2001}
-----------------------

A total of 138 newly diagnosed primary ESCC patients were included in the analysis, including 109 (79.0%) males and 29 (21.0%) females, with a median age of 65 years (range: 40--90 years). The number of patients with a tumor location of cervical, upper-thoracic, mid-thoracic or lower-thoracic was 13 (9.4%), 42 (30.4%), 64 (46.4%) and 19 (13.8%), respectively. There were 37 (26.82%) patients with stage Ⅱ disease and 101 (73.2%) patients with stage Ⅲ disease. Additionally, most of the patients experienced an OR type of primary tumor response (97, 70.3%); by comparison, 41 (29.7%) patients had a non-OR type of primary tumor response. Specifically, the rate of CR, PR, SD and PD was 4.35%(n=6), 58.60%(n=81), 27.54%(n=38), 2.17%(n=3), respectively. It was difficult to differentiate T2 from T3 lesions, so we divided patients into stage T1--3 vs T4.The baseline data regarding the clinicopathological parameters of the patients are summarized in [Table 1](#T0001){ref-type="table"}.Table 1Baseline Data Between Different SUVmax And LMR GroupsCharacteristicNo.SUV~max~LMR≤11.90\>11.90P≤2.76\>2.76PAge (y)0.8090.688 ≤6044(31.9%)14301727 \>6094(68.1%)28663361Gender0.1500.001 Male109(79.0%)30794762 Female29(21.0%)1217326Drinking history0.7210.117 Ever79(57.2%)25543346 Never59(42.8%)17421742Smoking history0.4870.602 Ever76(55.1%)25512947 Never62(44.9%)17452141Tumor location0.5460.123 Cervical13(9.4%)310211 Upper-thoracic42(30.4%)10322022 Mid-thoracic64(46.4%)23412044 Lower thoracic19(13.8%)613811cT status0.5700.151 T~1--3~111(80.4%)35767437 T~4~27(19.6%)7201314cN status0.7540.847 N~0~21(15.2%)714813 N~1--3~117(84.8%)35824275Tumor stage0.0170.173 II37(26.82%)17201027 III101(73.2%)25764061SUV~max~-0.933 ≤11.9042(30.4%)\--1527 \>11.9096(69.6%)\--3561LMR0.933- ≤2.7650(36.2%)1535\-- \>2.7688(63.8%)2761\--[^2]

Baseline SUVmax And Clinical Features {#S0003-S2002}
-------------------------------------

Receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cut-off value for SUVmax values: an area under the curve (AUC) of 0.682 was produced ([Figure 1](#F0001){ref-type="fig"}). The optimal cut-off value was 11.90 for the SUVmax; patients were stratified into two groups (the low-SUVmax group and the high-SUVmax group) on the basis of this cut-off. We found that SUVmax had predictive abilities for primary tumor response. The number of patients who obtained an OR type of primary tumor response was 36 in the low-SUVmax group versus 60 in the high-SUVmax group, with ORR values of 87.8% and 61.9%, respectively (P=0.004). We also found that patients with advanced-stage (III) disease had significantly higher SUVmax values than those with early-stage disease (p=0.017). Apart from those two features, none of the other parameters (i.e., age, gender, drinking history, smoking history, tumor location, clinical tumor stage, and clinical node stage) were associated with significant differences between the two groups ([Table 1](#T0001){ref-type="table"}).Figure 1ROC curve of SUVmax and NLR for primary tumor response prediction.**Notes:** The AUCs of LMR and SUVmax was 0.682(95% CI 0.598--0.759) and 0.667(95% CI 0.582--0.745) with the cut-off values was11.90, 2.76, respectively.**Abbreviations:** SUVmax, maximal standardized uptake value; LMR, lymphocyte--monocyte ratio.

Peripheral LMR And Clinical Features {#S0003-S2003}
------------------------------------

ROC analysis revealed that the cut-off point for peripheral LMR values was 2.76, with an AUC of 0.667 ([Figure 1](#F0001){ref-type="fig"}). From the comparisons, we found that 71 (80.7%) patients had an OR type of primary tumor response in the high-LMR group (LMR\>2.76), while there were only 26 (52.0%) patients who had an OR type of primary response in the low-LMR group (LMR≤2.76); this difference was statistically significant (P=0.001). Interestingly, there were gender differences between LMR groups: the proportion of women in the low-LMR group was larger than that in the high-LMR group (94.0% vs 70.5%, P=0.001). It may be due to the heterogenous distribution of female patients in different groups, which was caused by the low incidence of esophageal cancer in females. Regarding the other features, no statistically significant correlations were seen between different peripheral LMR groups ([Table 1](#T0001){ref-type="table"}).

Univariate And Multivariate Analyses Of The Primary Tumor Response {#S0003-S2004}
------------------------------------------------------------------

In univariate analysis, tumor stage (P=0.006, HR =0.210), SUVmax (P=0.004, HR =4.440) and LMR (P=0.001, HR =3.885) were associated with primary tumor response ([Table 2](#T0002){ref-type="table"}). Age (p=0.711), gender (p=0.461), drinking history (p=0.580), smoking history (p=0.554), tumor location (p=0.747), clinical tumor stage (p=0.166) and clinical node stage (p=0.252) showed no significant differences between the two groups ([Table 2](#T0002){ref-type="table"}). Multivariable logistic regression analyses were then performed, including the significant parameters (tumor stage, SUVmax and LMR). The results showed that tumor stage (P=0.026, HR =0.261; 95% CI: 0.080--0.850), SUVmax (P=0.007, HR=0220; 95% CI: 0.073--0.660) and LMR (P=0.001, HR=4.186; 95% CI: 1.821--9.624) were independent predictors of primary tumor response ([Table 3](#T0003){ref-type="table"}).Table 2Univariate Analysis For Primary Tumor Response (OR And Non-OR)CharacteristicTumor ResponseHR95% CIPOR (n=97)Non-OR (n=41) Age (y)1.1580.533--2.5160.711 ≤603014 \>606727Gender0.7020.274--1.8010.461 Male7534 Female227Drinking history1.2310.590--2.5670.580 Ever5722 Never4019Smoking history1.2470.600--2.5940.554 Ever5521 Never4220Tumor location1.0750.694--1.6650.747 Cervical103 Upper-thoracic2616 Mid-thoracic4816 Lower thoracic136cT status0.5390.225--1.2920.166 T~1--3~8130 T~4~1611cN status0.5090.160--1.6180.252 N~0~8037 N~1--3~174Tumor stage0.2100.069--0.6390.006 II334 III6437SUV~max~0.2250.081--0.6250.004 ≤11.90375 \>11.906036LMR3.8551.791--8.2990.001 ≤2.762624 \>2.767117[^3] Table 3Multivariate Analysis For Primary Tumor Response (OR And Non-OR)CharacteristicCategoriesHR95% CIPTumor stageII; III0.2610.080--0.8500.026SUV~max~≤11.90; \>11.900.2200.073--0.6600.007LMR≤2.76; \>2.764.1861.821--9.6240.001[^4]

Combined Predictive Value Of Baseline SUVmax And Peripheral LMR {#S0003-S2005}
---------------------------------------------------------------

Based on the optimal cut-off values of SUVmax and LMR, we divided the patients into four different groups: a low-SUVmax-high-LMR group (Group 1, G1; n=27), a low-SUVmax-low-LMR group (Group 2, G2; n=15); a high-SUVmax-high-LMR group (Group 3, G3; n=61), and a high-SUVmax-low-LMR group (Group 4, G4; n=35). The number of patients who obtained OR types of primary tumor response was 27 in G1, 15 in G2, 44 in G3 and 16 in G4, with ORRs of 100%, 66.7%, 72.1% and 45.7%, respectively. These differences were statistically significant (P\<0.001). We found that Group 1 had the highest ORR (100%), while Group 4 had the worst ORR (45.7%). To further explore whether there was a significant difference between the groups, we compared both Group 1 and Group 4 with the other three groups individually. The statistical analysis data showed that the P-values were 0.001, 0.002 and \<0.001 when Group 1 was compared with Group 2, Group 3 and Group 4, respectively. According to the Bonferroni correction, all P-values needed to be less than 0.0167 (α=0.05/3); therefore, these differences were statistically significant. However, when Group 4 was compared with the other three groups, only the comparisons with Group 1 and Group 3 were statistically significant (P\<0.001 and P=0.010), while the comparison with Group 2 was not (P=0.174) ([Table 4](#T0004){ref-type="table"}).Table 4Compare Between Different Groups Based On SUV~max~ -LMR StatusGroupsParameterORRComparedPsPSUV~max~LMR(%)GsG1(n=27)8.0±2.85.0±1.7100%G20.001\<0.001G30.002G4\<0.001G2(n=15)9.0±2.32.1±0.366.7%G30.676G40.174G3(n=61)18.9±4.24.0±1.072.1%G40.010G4(n=35)20.4±6.72.2±0.445.7%----[^5][^6]

Discussion {#S0004}
==========

In this study, we retrospectively analyzed a series of newly diagnosed ESCC patients who underwent PET/CT and routine blood tests before treatment. Baseline SUVmax combined with peripheral LMR can be used as an effective indicator to predict the clinical primary tumor response for patients who are treated with CCRT. To the best of our knowledge, this is the first study to consider both abnormal glucose metabolism by tumor cells and the anti-tumor immune response of the host.

Approximately 100 years ago, Otto Warburg observed that, in order to survive and grow in host tissue, tumor cells had high rates of glycolysis despite the presence of oxygen.[@CIT0007],[@CIT0008] This increased glucose metabolism by tumor cells is considered an important factor affecting tumor biology and manifests as increased FDG uptake. Previous studies have shown that the baseline SUVmax of primary tumors has potential value for predicting treatment response in lung cancer, cervical cancer and lymphoma. In those studies, patients with higher SUVmax values are more likely to have poor primary tumor responses.[@CIT0010]--[@CIT0014] In this study, we divided 138 newly diagnosed inoperable treated ESCC patients into a high-SUVmax group and a low-SUVmax group using a cut-off SUVmax value of 11.90. We found that the number of who achieved an OR in the low-SUVmax group was higher than that in the high-SUVmax group, and more patients were in the low-SUVmax group overall. Patients with lower SUVmax values had better primary tumor responses. These results are supported by the study by Suzuki A et al,[@CIT0015] in which the analysis of 179 esophageal or gastroesophageal carcinoma patients showed that patients who reached clinical complete response after definitive CCRT had a median SUV of 10.2, whereas those who did not achieve a clinical complete response had a median SUV of 15.3. Kato H et al[@CIT0016] have reported similar findings, reporting that the median SUV of the patients who reached a CR was 4.9, compared with 10.2 in non-CR patients. In our analysis, age, gender, drinking history, smoking history, tumor location, cT status, cN status, and peripheral LMR were not associated with baseline SUVmax. Univariate and multivariate analyses confirmed that baseline SUVmax is an independent predictor of primary tumor response.

The immune system and inflammation play an important role in the development, progression and metastasis of tumors.[@CIT0021],[@CIT0022] As an essential component of acquired immunity and innate immunity, lymphocytes can mediate the death of cytotoxic cells and inhibit the proliferation and metastasis of tumor cells.[@CIT0031],[@CIT0032] Changes in lymphocyte populations can reflect the condition of the immune system of the host, and a decrease in lymphocytes in the tumor microenvironment indicates a weak and insufficient anti-tumor immune response.[@CIT0032],[@CIT0033] Monocytes are also important immune cells in the host. They can change the tumor microenvironment by inhibiting local immunity and angiogenesis, thereby promoting the occurrence and distant metastasis of tumors.[@CIT0034],[@CIT0035] Moreover, as part of the host immune system, circulating immune cells play a critical role in tumor progression. Peripheral LMR can reflect the host immune status and immune response to tumors. Moreover, it has been reported that LMR, as a simple and accessible indicator of the circulating levels of lymphocytes and monocytes, is correlated with the tumor-infiltrating lymphocyte/tumor-associated macrophage ratio, suggesting that it may reflect the immune state of the tumor microenvironment.[@CIT0036] A low peripheral LMR was first reported to be associated with poor prognosis in Hodgkin's lymphoma and diffuse large B cell lymphoma.[@CIT0023],[@CIT0024] Subsequently, the correlation of baseline peripheral LMR with primary tumor response was reported in other solid tumors, such as nasopharyngeal carcinoma, lung cancer, colorectal cancer, and ovarian cancer.[@CIT0025]--[@CIT0028] Regarding esophageal cancer, Huang et al[@CIT0029] retrospectively analyzed data from 348 patients with esophageal squamous cell cancer who underwent radical surgery and found that the 5-year cancer-specific survival was significantly lower for patients with a peripheral LMR ≤ 2.93 than for patients with a peripheral LMR \>2.93. Han et al[@CIT0030] reported that host peripheral LMR is an independent prognostic factor for long-term survival in ESCC patients who have undergone radical surgery. The disease-free survival and overall survival of patients in the low-peripheral-LMR group were significantly lower than those in the high-peripheral-LMR group. However, these two studies focused on surgical EC patients and the relationship between peripheral LMR and long-term survival. Our previous research[@CIT0037] analyzed the correlation between peripheral LMR and tumor response in 162 ESCC patients who received definitive CCRT. In this study, we used the median value of the pre-treatment LMR (4.02) as the cut-off value. It indicated that the baseline peripheral LMR was a significant prognostic factor for a better clinical tumor response. Thirty-six patients had a CR in the high-peripheral-LMR (\>4.02) group, while twelve in the low-peripheral-LMR (≤4.02) group had a CR. Although we already knew that peripheral LMR could predict clinical tumor response, in this previous study we were unable to determine the sensitivity and specificity of this parameter because we used a median value as the cut-off point for peripheral LMR. In the present study, the optimal cut-off value for peripheral LMR was determined by ROC analysis, providing a better determination of sensitivity and specificity. Patients with a higher peripheral LMR were more likely to have an OR type of primary tumor response than those with a lower peripheral LMR. In univariate and multivariate analyses, peripheral LMR was a significant predictive factor for primary tumor response.

Definitive CCRT is the main treatment for patients with EC who cannot undergo surgery. However, there is a difference in the treatment response of individuals. The main reason is that it is difficult to make an "individualized" CCRT choice for patients. Therefore, early prediction of tumor response is necessary, as it can identify which patients are sensitive or insensitive to CCRT before treatment and more accurately classify these patients. We hypothesized that tumor cells and host immune status were the main factors affecting tumor response to CCRT. Accordingly, we explored the combined predictive value of baseline SUVmax and peripheral LMR for tumor response in patients with ESCC undergoing CCRT. In this study, the group containing patients who had lower SUVmax values accompanied by higher peripheral LMRs achieved the best primary tumor response compared with the other three groups, and their ORR was 100%. Meanwhile, although the ORRs were different, there were no statistical differences between the high-SUVmax-low-LMR group and the low-SUVmax-low-LMR group. This may be due to the small sample size of the low-SUVmax-low-LMR group. When the high-SUVmax-low-LMR group was compared with the low-SUVmax-high-LMR group and the high-SUVmax-high-LMR group, the differences were statistically significant, and both of these groups had larger sample sizes. In summary, for inoperable treated ESCC patients, those with lower FDG uptake accompanied by a higher peripheral LMR may be more sensitive to CCRT, and an aggressive treatment strategy is needed. However, those with higher FDG uptake accompanied by a lower peripheral LMR may be relatively insensitive to treatment, and their treatment strategies may need to be modified early on during treatment, such as tailoring the intensity of treatment or combining targeted therapies, and monitored more carefully of response.

The main limitations of this study are that it is a retrospective, single-center study with a small sample size. There are potential confounding factors that we cannot control. Therefore, a prospective, multicenter, clinical and large-scale trial is needed to confirm our results. Second, although we have applied endoscopic ultrasonography, enhanced CT and PET/CT, clinical TNM staging is still not as accurate as pathological TNM staging. Third, the possible relationship between SUVmax and peripheral LMR in our study was unclear. Thus, further research is needed to obtain a more detailed explanation.

Conclusion {#S0005}
==========

ESCC patients who have lower FDG uptake accompanied by a higher peripheral LMR are more likely to have a good primary tumor response after CCRT, while those who have higher FDG uptake accompanied by a lower peripheral LMR are more likely to have a poor one. These findings may help clinicians identify subgroups of patients who are sensitive or insensitive to CCRT, thus allowing patients to receive individualized and accurate treatment.
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